Confocal Laser Endomicroscopy Reveals Differential Response in Patients with Active Ulcerative Colitis Undergoing Anti-Integrin Compared to Anti-Tnf-Alpha Therapy

Aims Mucosal healing is the central goal of therapy in ulcerative colitis(UC) but is only based on superficial criteria that do not allow assessment of early therapy response. Confocal Laserendomicroscopy(CLE) enables visualisation of dynamic changes of the mucosa and might reliably exhibit very early changes of the architecture. To evaluate CLE for dynamic quantification of the level of inflammation in UC patients undergoing biological therapy (Vedolizumab(VDO) or Infliximab(IFX)) as a marker for early therapy response.